Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
MOLOGEN AG Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
The Berlin-based biotech company, MOLOGEN, is moving swiftly forward with its preparations for starting the clinical study on the innovative cancer medicine, MGN1703. The aim is to start with patient consumption in a few weeks time. MGN1703 is based on the DNA immunomodulator dSLIM® developed by MOLOGEN. The quantities of the Investigational Medicinal Product MGN1703 required for the clinical study have already been produced and are all available. Together with the study centers, university hospitals in Essen and Cologne, the organizational and logistical procedures required to ensure an optimum study are currently being prepared. The last formal specifications of the approval and licensing authorities were met in the past few days.
Speaking about the preparatory work, Dr. Matthias Schroff, Chief Executive Officer of MOLOGEN AG said: "The preparations for starting the clinical study with MGN1703 on schedule are going full steam ahead. I expect that we will be able to bring the first patients into the study in a few weeks time."
Information about the clinical study with MGN1703 The planned study (Phase I) of the safety, compatibility and immunological effect of MGN1703 in the treatment of various cancers is a major milestone for a comprehensive clinical development program. MOLOGEN plans to establish an effective, compatible treatment for the treatment of the most frequent cancers in the form of MGN1703. According to forecasts from experts, there is a global market worth several billion dollars for innovative, immunomodulatory forms of cancer therapy. The study is to be performed at the renowned cancer centers in university hospitals in Essen and Cologne, and will last around six months.
dSLIM® - an innovative TLR9 agonist In dSLIM® ("double Stem Loop Immunomodulator"), MOLOGEN has developed an innovative TLR9 agonist. Use of dSLIM® activates the immune system to protect against tumor-associated antigens by targeting the TLR9 receptor on certain immune cells. As a result of chemotherapy and radiotherapy, tumor-associated antigens are released by cancer cells. The immune system activated by dSLIM® is in a position to overcome its fatal tolerance towards cancer cells and advance against them strategically.
Market for immunomodulatory therapies worth billions In terms of efficacy and compatibility, immunomodulatory therapies could mean a real medical breakthrough in the fight against cancer. Experts estimate that there is a global market worth billions of US Dollars for such therapies. Pharmaceutical companies are therefore extremely interested in securing the rights to molecules like TLR9 agonist and testing substances in many different indications. The recent acquisition of a US competitor by a globally operating pharmaceutical group is convincing proof of the great potential attributed internationally to TLR technology.
About MOLOGEN MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures (DNA: deoxyribonucleic acid). Its patented DNA-based platform technologies MIDGE® and dSLIM® form a universal foundation with a wide range of possible applications. Activities focus on product developments for the treatment of cancer and vaccines for serious infections in humans and animals. MOLOGEN was founded in 1998 and was the first German biotechnology company to go public. MOLOGEN AG shares are listed in the General Standard of Deutsche Börse (ISIN DE 0006637200).
Disclaimer concerning prognoses Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.
WKN: 663720; ISIN: DE0006637200; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, General Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;
